Please ensure Javascript is enabled for purposes of website accessibility

Is Johnson & Johnson Now a Has-Been in the COVID Vaccine Market?

By Keith Speights and Brian Orelli, PhD - Updated Jun 22, 2021 at 5:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In some ways, yes.

Johnson & Johnson (JNJ 0.48%) was once viewed as a leader in the COVID-19 vaccine arena. However, various issues have changed that perception in the minds of some. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J is now a has-been in the COVID-19 vaccine market.

Keith Speights: Reuters recently reported about another company, Johnson & Johnson. Johnson & Johnson is a big player in healthcare -- period. But they're one of the companies that has an authorized COVID-19 vaccine on the market.

Well, Reuters recently reported that demand for J&J's COVID-19 vaccine has stalled. With the prospects even that some doses could expire unused. Brian, what's the situation with Johnson & Johnson here, and is the company basically a has-been in the COVID-19 vaccine market, or can it turn things around?

Brian Orelli: Johnson & Johnson should have been a big winner here because it's a one-and-done vaccine, and it has easier storage requirements. It should have been a clear choice. But the lower efficacy and then probably, more importantly, the potential for blood clots have lowered demand.

I saw one stat that said it was, I don't know, as little as five percent of total vaccinations given are the Johnson & Johnson vaccines. Johnson & Johnson has been trying to profit during the pandemic. It will presumably transfer the US order to the government and get paid. Then presumably the government would then donate the vaccine to other countries, especially in countries where it might be really difficult to get the patients back for their second vaccine. Johnson & Johnson is more beneficial there than in the United States.

I don't really think that Johnson & Johnson is set up to profit from the coronavirus post-pandemic anyway because their vaccine uses a virus to deliver DNA that encodes the coronavirus. I think they're likely to develop immunity to the viral vector, so any booster shots will become less and less effective with Johnson & Johnson's vaccine. That makes it one and done advantages, also it's one and done disadvantaged in that it probably isn't going to be used as a booster compared to the mRNA vaccines.

Speights: Maybe Johnson & Johnson isn't has been; it's a never was.

Orelli: Yeah.

Brian Orelli, PhD has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$166.09 (0.48%) $0.79

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.